Biological therapy for lupus nephritis-tribulations and trials

Nature Reviews Rheumatology

Volumn 6, Issue 9, 2010, Pages 547-552

  Smith, Rona M ^a   Clatworthy, Menna R ^a   Jayne, David R W ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABETIMUS; ALEMTUZUMAB; ATACICEPT; AZATHIOPRINE; BELIMUMAB; BIOLOGICAL PRODUCT; BORTEZOMIB; CALCINEURIN INHIBITOR; COMPLEMENT INHIBITOR; CYCLOPHOSPHAMIDE; EDRATIDE; EPRATUZUMAB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MDX 1342; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; OFATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PREDNISOLONE; RITUXIMAB; RUPLIZUMAB; STEROID; SYNTHETIC PEPTIDE; THYMOCYTE ANTIBODY; TORALIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B LYMPHOCYTE ACTIVATION; BIOLOGICAL THERAPY; CELL SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; HUMAN; IMMUNE DYSREGULATION; IMMUNOMODULATION; INFECTION RATE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PLASMA CELL; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM;

ADJUVANTS, IMMUNOLOGIC; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; LYMPHOCYTE DEPLETION; PLASMA CELLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 77956289643     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2010.117     Document Type: Review

References (40)

1. Borchers, A. T., Keen, C. L., Shoenfeld, Y. & Gershwin, M. e. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun. Rev. 3, 423-453 (2004).
2. Cervera, R. et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82, 299-308 (2003).
3. Björnådal, L., Yin, L., Granath, F., Klareskog, L. & ekbom, A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-1995. J. Rheumatol. 31, 713-719 (2004).
4. Clatworthy, M. R. & Smith, K. G. B cells in glomerulonephritis: focus on lupus nephritis. Semin. Immunopathol. 29, 337-353 (2007).
5. Sanz, I. & Lee, F. e. H. B cells as therapeutic targets in SLe. Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2010.68.
6. Genentech press release. Genentech and Biogen Idec announce top-line results from phase II/III clinical study of rituxan in systemic lupus erythematosus. http://www.gene.com/ [online], http://www.gene.com/gene/news/ press-releases/display.do-method=detail &id=11247 (2008).
7. Genentech press release. phase III study of rituxan in lupus nephritis did not meet primary endpoint. http://www.gene.com/ [online], http://www.gene.com/gene/news/ press-releases/display.do-method=detail &id=11947 (2009).
8. pepper, R. et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol. Dial. Transplant. 24, 3717-3723 (2009).
9. US National Library of Medicine. A study to evaluate ocrelizumab in patients with nephritis due to systemic lupus erythematosus (BeLONG). ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT00626197 (2010).
10. Roche press release. Roche, Genentech and Biogen Idec announce positive results from first phase III trial of ocrelizumab in rheumatoid arthritis. http://www.roche.com/ [online], http://www.roche.com/med-cor-2009-12-11b (2009)
11. Dörner, T. et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8, R74 (2006).
12. Jacobi, A. M. et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann. Rheum. Dis. 67, 450-457 (2008).
13. UCB press release. UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLe). http://www.ucb.com/ [online], http://www.ucb.com/media-room/ newsdetail/?det=1337304 (2009).
14. Barber, D. F. et al. pI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11, 933-935 (2005).
15. US National Library of Medicine. Study of the safety of MDX-1342 in combination with methotrexate in patients with rheumatoid arthritis (MDX1342-01). ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT00639834 (2010).
16. Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748-755 (2008).
17. Khare, S. D. et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc. Natl Acad. Sci. USA 97, 3370-3375 (2000).
18. Stohl, W. et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48, 3475-3486 (2003).
19. petri, M. et al. Four year experience of belimumab, a BLyS-specific inhibitor in systemic lupus erythematosus (SLe) patients [abstract 2069]. Arthritis Rheum. 60 (Suppl.), S774 (2009).
20. GlaxoSmithKline press release. GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of benlysta in systemic lupus erythematosus. http://us.gsk.com/ [online], http://us.gsk.com/ html/media-news/pressreleases/2009/ 2009-pressrelease-10121.htm (2009).
21. pena-Rossi, C. et al. An exploratory doseescalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18, 547-555 (2009).
22. Alarcon-Segovia, D. et al. LJp 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebocontrolled study. Arthritis Rheum. 48, 442-454 (2003).
23. Cardiel, M. H. et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 58, 2470-2480 (2008).
24. Mok, C. C., Tong, K. H., To, C. H., Siu, Y. p. & Au, T. C. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an openlabeled pilot study. Kidney Int. 68, 813-817 (2005).
25. Boumpas, D. T. et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48, 719-727 (2003).
26. Merrill, J. et al. The efficacy and safety of abatacept in SLe: results of a 12 month exploratory study [abstract L15]. presented at the 2008 ACR/ARHp Annual Scientific Meeting.
27. US National Library of Medicine. Abatacept and cyclophosphamide combination therapy for lupus nephritis (ACCeSS). ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/ NCT00774852 (2010).
28. Daikh, D. I. & Wofsy, D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166, 2913-2916 (2001).
29. Teva press release. Teva provides update on edratide for systemic lupus erythematosus. http://www.tevapharm.com/ [online], http://www.tevapharm.com/pr/ 2007/ pr-689.asp (2007).
30. Sthoeger, Z. M. et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (edratide): immunomodulation of gene expression. J. Autoimmun. 33, 77-82 (2009).
31. Bloom, D. D. et al. CD4+ CD25+ FOXp3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with campath-1H. Am. J. Transplant. 8, 793-802 (2008).
32. Baechler, e. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610-2615 (2003).
33. Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003).
34. Wallace, D. J. et al. MeDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus [abstract 1315]. Arthritis Rheum. 56 (Suppl.), S526-S527 (2007).
35. Illei, G. G. et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 62, 542-552 (2010).
36. Aringer, M. et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 48, 1451-1454 (2009).
37. Rother, R. p., Mojcik, C. F. & McCroskery, e. W. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 13, 328-334 (2004).
38. Bertsias, G. et al. eULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the eULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann. Rheum. Dis. 67, 195-205 (2008).
39. Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011-1016 (2008).
40. Weng, W. K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003).